HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): David B. Ross Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ross, D. B. Search for Related Content PubMed Articles by Ross, D. B. Related Collections Molecular biology

Ann Thorac Surg 2004;77:1739
© 2004 The Society of Thoracic Surgeons

Invited commentary

University of Alberta Hospital, 2D4.37 Walter MacKenzie Health Sciences, 8440 112th St, Edmonton, AB, T6G 2B7 Canada

e-mail: dbross@cha.ab.ca

The first 20% of the full text of this article appears below.

Shady and colleagues have demonstrated in this small pilot study that mycophenolic mofetil can significantly, but incompletely, reduce the development of antibodies to HLA class I (but not class II) antigens following implantation of valved allografts in children undergoing cardiac surgery. This study builds on their previous work that clearly demonstrates that implanting cardiac allograft tissue results in the development of donor specific antibodies lasting at least one year in these children. That cardiac allograft tissue elicits a powerful and sustained immunological reaction is well established. Whether attenuating this response is beneficial . . . [Full Text of this Article]